ReviewThe Yale journal of biology and medicine2020
The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.
Review in The Yale journal of biology and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 68 citations in OpenAlex.
- Organ Involvement and Treatment Response across Cutaneous Sarcoidosis Subtypes.Acta dermato-venereologica · 2026Article
- SPT6 maintains epidermal homeostasis by inhibiting an NF-κB-positive feedback loop to prevent excessive inflammation.Cellular & molecular immunology · 2026Article
- Melkersson-Rosenthal syndrome and upadacitinib: A case report.JAAD case reports · 2026Article
- Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach.Seminars in respiratory and critical care medicine · 2025Review
- Pulmonary hypertension associated with sarcoidosis: current and future treatment landscape.Future cardiology · 2025Article
- Tofacitinib-Induced Steroid-Free Remission in Subcutaneous Sarcoidosis With Neurologic Involvement: A Case Report.Cureus · 2025Article
- JAK inhibitors for the treatment of rheumatoid nodules.JAAD case reports · 2025Article
- COVID-19 infection and pulmonary sarcoidosis: a systematic review and meta-analysis of morbidity, severity and mortality.Journal of thoracic disease · 2025Article
- Sarcoidosis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies.Reviews in cardiovascular medicine · 2025Review
- Successful Treatment of Cutaneous Foreign Body Granuloma with JAK Inhibitor Abrocitinib and Prednisone: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Overview of multi-omics approaches for pulmonary sarcoidosis.EC pulmonology and respiratory medicine · 2025Article
- Successful Treatment of Delayed Onset Nodules After Dermal Fillers Injection with Abrocitinib: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- The New Frontier of JAK Inhibitors: Significant Therapeutic Response to Tofacitinib in a Patient With Granulomatous Reaction to Filler in the Buttocks.Journal of cosmetic dermatology · 2024Article
- Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders.The Journal of allergy and clinical immunology · 2024Article
- Article
- Recalcitrant cutaneous sarcoidosis treated with upadacitinib: Case report.JAAD case reports · 2024Article
- Seronegative cutaneous rheumatoid nodules with positive response to tofacitinib.JAAD case reports · 2024Article
- Microblading reaction as a manifestation of systemic sarcoidosis: two case reports and a review of the literature.Journal of medical case reports · 2024Review
- A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Certain inflammatory disorders are characterized by macrophage activation and accumulation in tissue; sometimes leading to the formation of granulomas, as in sarcoidosis. These disorders are often difficult to treat and more effective, molecularly targeted therapies are needed. Recent work has shown that overproduction of inflammatory cytokines, such as interferon gamma (IFN-γ) leading to constitutive activation of the JAK-STAT pathway may be a conserved feature of these disorders. Use of JAK inhibitors, which can block these signals, has resulted in dramatic improvement in several patients with sarcoidosis. JAK inhibitors also appear to have activity in other inflammatory disorders with macrophage activation including hemophagocytic lymphohistiocystosis, Crohn's disease, granuloma annulare, and necrobiosis lipoidica. Here, we review the role of JAK dependent cytokines in macrophage activation and granuloma formation and the clinical evidence supporting the use of JAK inhibition in these disorders. Ongoing efforts to evaluate role of JAK inhibitors in these disorders is also discussed.
Indexed as
Identifiers
32226347PMC7087061W3013950525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.